{"id":"W2979619193","doi":"10.1182/blood.v122.21.4009.4009","title":"ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Medicine; Tolerability; Adverse effect; Internal medicine; Clinical endpoint; Clinical trial; Interim analysis; Imatinib; Oncology; Myeloid leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003259311,0.0005960535,0.001408561,0.0002365047,0.0002169901,0.0009367285,0.0006038061,0.0004370681,0.002144111],"category_scores_gemma":[0.001963914,0.000202716,0.001028361,0.0002321607,0.0004584173,0.0007945035,0.0004332301,0.001479515,0.0002478666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008466726,"about_ca_system_score_gemma":0.001251299,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004456146,"about_ca_topic_score_gemma":0.001871411,"domain_scores_codex":[0.9987233,0.0007549499,0.0000881999,0.0001822899,0.0001274319,0.0001238386],"domain_scores_gemma":[0.999079,0.0002567742,0.0002595793,0.0001035173,0.0000551456,0.0002458757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7214485,0.02407838,0.02991372,0.0006658275,0.00184314,0.0002517046,0.0001763298,0.01251948,0.04984518,0.0003802364,0.002448919,0.1564287],"study_design_scores_gemma":[0.1655315,0.6975382,0.0824473,0.00008129312,0.001733649,0.0006880988,0.000175027,0.01157796,0.02956346,0.0005368205,0.01005162,0.0000751364],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953026,0.001335508,0.0005967078,0.0001828751,0.00004389301,0.0007607411,0.0006270102,0.00003912512,0.001111449],"genre_scores_gemma":[0.9948406,0.0003416646,0.001679785,0.0001915476,0.00004396175,0.0005069359,0.00130788,0.00001388375,0.001073769],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003259311,"threshold_uncertainty_score":0.01723713,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01147851987796914,"score_gpt":0.275172306118641,"score_spread":0.2636937862406719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}